Abbott Laboratories (ABT) revenue by segment
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3034% above fair value
$104.48−0.23 (-0.22%)
Close on Nov 18, 2026Market cap $180.79BP/E 33.6Yield 2.30%
Doanh thu theo bộ phận của Abbott Laboratories
Theo bộ phận kinh doanh
| Doanh thu | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medical Devices | $21.39B | $18.99B | $16.89B | $14.80B | $14.49B | $11.79B | $12.24B | $11.37B | $10.33B | – | 48.2% | +12.6% |
| Diagnostic Products | $8.94B | $9.34B | $9.99B | $16.47B | $15.53B | $10.81B | $7.71B | $7.50B | $5.62B | $4.81B | 20.2% | -4.3% |
| Nutritional Products | $8.45B | $8.41B | $8.15B | $7.46B | $8.29B | $7.65B | $7.41B | $7.23B | $6.93B | $6.90B | 19.1% | +0.5% |
| Established Pharmaceuticals | $5.54B | $5.19B | $5.07B | $4.91B | $4.72B | $4.30B | $4.49B | $4.42B | $4.29B | $3.86B | 12.5% | +6.6% |
| Other Segment | – | – | – | – | $52.00M | $66.00M | $57.00M | $62.00M | $237.00M | $2.39B | – | – |
| Cardiovascular and Neuromodulation Products | – | – | – | – | – | – | – | $9.44B | $8.91B | $2.90B | – | – |
| Vascular Products | – | – | – | – | – | – | – | – | – | $2.90B | – | – |
| Lợi nhuận hoạt động | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Medical Devices | $7.21B | $6.15B | $5.31B | $4.44B | $4.53B | $3.04B | $3.77B | $3.50B | $3.01B | – | +17.2% |
| Diagnostic Products | $1.74B | $2.07B | $2.43B | $6.64B | $6.24B | $3.73B | $1.91B | $1.87B | $1.47B | $1.19B | -16.1% |
| Nutritional Products | $1.56B | $1.51B | $1.33B | $706.00M | $1.76B | $1.75B | $1.71B | $1.65B | $1.59B | $1.66B | +3.5% |
| Established Pharmaceuticals | $1.29B | $1.23B | $1.21B | $1.05B | $889.00M | $794.00M | $904.00M | $894.00M | $848.00M | $723.00M | +4.6% |
| Cardiovascular and Neuromodulation Products | – | – | – | – | – | – | – | $2.99B | $2.72B | $1.04B | – |
| Vascular Products | – | – | – | – | – | – | – | – | – | $1.04B | – |
Theo sản phẩm hoặc dịch vụ
Theo khu vực
| Doanh thu | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % doanh thu | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| International | $27.20B | $25.63B | $24.66B | $25.51B | $26.43B | $21.59B | $20.51B | $19.74B | $17.72B | – | 61.4% | +6.1% |
| United States | $17.13B | $16.32B | $15.45B | $18.14B | $16.64B | $13.02B | $11.40B | $10.84B | $9.67B | $6.49B | 38.6% | +4.9% |
| All Other Countries | $15.98B | $14.79B | $14.17B | $15.01B | $15.73B | $12.82B | $11.94B | $11.22B | $9.94B | $7.96B | 36.0% | +8.1% |
| Germany | $2.76B | $2.54B | $2.35B | $2.34B | $2.57B | $2.11B | $1.75B | $1.62B | $1.37B | $1.04B | 6.2% | +8.7% |
| China | $1.91B | $2.11B | $2.25B | $2.13B | $2.39B | $1.97B | $2.35B | $2.31B | $2.15B | $1.73B | 4.3% | -9.7% |
| India | $1.87B | $1.82B | $1.75B | $1.65B | $1.56B | $1.32B | $1.40B | $1.33B | $1.24B | $1.11B | 4.2% | +3.0% |
| Switzerland | $1.87B | $1.75B | $1.64B | $1.34B | $1.31B | $1.14B | $1.07B | $1.01B | $841.00M | $766.00M | 4.2% | +7.1% |
| Japan | $1.48B | $1.44B | $1.51B | $1.93B | $1.70B | $1.39B | $1.44B | $1.33B | $1.26B | $924.00M | 3.3% | +2.4% |
| United Kingdom | $1.34B | $1.19B | $991.00M | – | – | – | – | – | $498.00M | $377.00M | 3.0% | +13.1% |
| Netherlands | – | $1.12B | $1.07B | $1.11B | $1.17B | $1.08B | $975.00M | $930.00M | $929.00M | $830.00M | – | – |
| Canada | – | – | – | $1.28B | $1.39B | $841.00M | $573.00M | – | $443.00M | $408.00M | – | – |
| Italy | – | – | – | – | – | – | – | – | $507.00M | $365.00M | – | – |
| Brazil | – | – | – | – | – | – | – | – | $541.00M | $410.00M | – | – |
| Russia | – | – | – | – | – | – | – | – | $664.00M | $554.00M | – | – |
| Colombia | – | – | – | – | – | – | – | – | $494.00M | $424.00M | – | – |
| Vietnam | – | – | – | – | – | – | – | – | $427.00M | $434.00M | – | – |
| France | – | – | – | – | – | – | – | – | $628.00M | $352.00M | – | – |
Lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K, 10-Q của Abbott Laboratories (XBRL). Số quý 4 bằng cả năm tài chính trừ chín tháng đầu. Tên bộ phận giữ theo cách công ty tự đặt và có thể đổi khi công ty tái cấu trúc. Tab KPI hiện các bộ phận này cạnh chỉ số vận hành của Abbott Laboratories, kèm đầy đủ lịch sử, biểu đồ và liên kết tới từng hồ sơ.
See a number that looks wrong?